GLP1R and alkaline phosphatase measurement: The current FDA labels of GLP-1 agonists warn of pancreatitis as an adverse event and advise holding these agents promptly if AP develops and not restarting them in such cases; however, a prior history of pancreatitis is not regarded as a contraindication to starting GLP-1 agonists [48,49].